Dr. David Rawlings, director of Seattle Children’s Center for Immunity and Immunotherapies and a scientific co-founder of GentiBio
Biotechnology start-up GentiBio — a Seattle Children’s Research Institute spin-out — announced a multi-year collaboration with global pharmaceutical company Bristol Myers Squibb, the latest success story in the research institute’s rapid development of therapies and technologies that change children’s lives. Spin-off companies and biotechnology/pharmaceutical industry collaborations are a critical part of accelerating and expanding the reach of these innovations.
GentiBio is collaborating with Bristol Myers Squibb to develop new engineered regulatory T cell (Treg) therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases, which cause debilitating and life-threatening chronic inflammation of the gastrointestinal tract. Current therapies are largely focused on systemic anti-inflammatories and broad immunosuppression, which can cause adverse effects and are not curative.
